New pill aims to boost red blood cells in cancer patients

NCT ID NCT06075043

Not yet recruiting Symptom relief Sponsor: Kind Pharmaceuticals LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests an oral drug called AND017 for anemia (low red blood cells) in cancer patients who are not receiving chemotherapy. The study will enroll 36 participants to see if different doses of AND017 can safely raise hemoglobin levels over 6 weeks. The goal is to reduce the need for blood transfusions and improve energy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AND017
What this could lead to: If successful, this could offer a new oral treatment option for anemia in cancer patients, potentially reducing the need for blood transfusions.
What could go wrong: This is an early Phase 2 trial with only 36 participants, so results may not apply broadly. The drug may not effectively raise hemoglobin or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates